Drug Profile
Research programme: B cell targeted monoclonal antibody - Oncotelic Therapeutics
Alternative Names: OXiMAb 24ALatest Information Update: 30 Apr 2021
Price :
$50
*
At a glance
- Originator Intracel Corporation
- Developer Mateon Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 17 Jun 2016 OXiGENE is now called Mateon Therapeutics
- 30 Apr 2007 Preclinical trials in Cancer in USA (Parenteral)